News & Media
News Updates
Arabic, Italian, and Spanish-language websites unlock commercial access to regions representing over 1.4 billion people Multilingual rollout aligns with product readiness and accelerates international sales pipeline development NEW YORK, May
Company expands Intelligent Fingerprinting Drug Screening System multilingual capabilities to meet growing demand across Latin American Spanish-speaking markets Latin American drug screening market projected to reach USD 1.1 billion by
Testing for illicit drug use has been readily available since the 1960s. Initially, those suspected of drug use would be required to submit a blood, hair, urine, or saliva sample
Discover how the Intelligent Fingerprinting Drug Testing Solution works via our easy-to-follow fingerprint drug testing demo. The Intelligent Fingerprinting Drug Screening System is quick and easy to use, detecting commonly
Integration of Arabic opens opportunities in the Middle East and supports Company’s strategic global expansion goals NEW YORK, March 31, 2025 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or
INBS set to capitalize on growing Spanish Drug Testing Market, anticipated to reach $448 million by 2030 Major Spanish accounts currently require 1,000 drug testing cartridges per month NEW YORK,
Company’s 6th U.S. patent adds to comprehensive IP portfolio protecting its unique drug screening technology Patent protection strengthens Company’s competitive position as it prepares for planned entry into multi-billion dollar
NEW YORK, March 25, 2025 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today provided shareholders with a
Non-Invasive Drug Testing at the Tips of Your Fingers Traditional drug testing methods can be intrusive, undignified, and uncomfortable for both test takers and administrators. The Intelligent Fingerprinting Drug Screening
NEW YORK, March 20, 2025 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that it expects
Gross profit increase of 32.6% and 11-point gross profit margin increase driven by higher-margin cartridge sales Submitted FDA 510(k) and remain on track for planned expansion into multi-billion dollar U.S.
Company highlights key milestones achieved in 2024, growing revenues and progress towards U.S. expansion in 2025 NEW YORK, February 10, 2025 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or
Media
